首页> 美国卫生研究院文献>Journal for Immunotherapy of Cancer >A novel TLR4 binding protein 40S ribosomal protein S3 has potential utility as an adjuvant in a dendritic cell-based vaccine
【2h】

A novel TLR4 binding protein 40S ribosomal protein S3 has potential utility as an adjuvant in a dendritic cell-based vaccine

机译:一种新型的TLR4结合蛋白40S核糖体蛋白S3具有潜在的实用性可作为基于树突细胞的疫苗的佐剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundDendritic cells (DCs) are professional antigen presenting cells (APCs), which can activate antigen-specific CD8+ T cell immunity, resulting in tumor clearance. Immature DCs are usually stimulated by various adjuvants through their immune receptors. Among them, Toll-like receptor 4 (TLR4) has an important role in activating DCs to cause their maturation. In fact, TLR4 is well-known to induce innate and adaptive immune responses against various external microbial or internal damage associated molecular patterns (DAMP). LPS is widely regarded as a strong stimulator of TLR4 signaling. However, LPS is inappropriate for use in humans since it is an endotoxin. Unfortunately, other TLR4 ligands such as HMGB1 or heat shock proteins have weak adjuvant effects. Therefore, there is a need to identify novel, biocompatible, strong, TLR4 ligands.
机译:背景树突细胞(DC)是专业的抗原呈递细胞(APC),可以激活抗原特异性CD8 + T细胞免疫力,从而清除肿瘤。不成熟的DC通常通过其免疫受体被各种佐剂刺激。其中,Toll样受体4(TLR4)在激活DC以使其成熟方面具有重要作用。实际上,众所周知,TLR4可以诱导针对各种外部微生物或内部损伤相关分子模式(DAMP)的先天性和适应性免疫反应。 LPS被广泛认为是TLR4信号的强大刺激剂。但是,LPS是内毒素,因此不适合在人类中使用。不幸的是,其他TLR4配体(例如HMGB1或热激蛋白)的佐剂作用较弱。因此,需要鉴定新的,生物相容性强的TLR4配体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号